The Launchpad Program offered by Polygon Health Analytics is a comprehensive 3-to-6-month train-to-hire program tailored for those intrigued by real-world data (RWD)real-world evidence (RWE), and health economics and outcomes research (HEOR). Whether you’re a recent graduate in computer science, statistics, data sciences, or epidemiology, or an experienced professional considering a career shift from medical affairs, clinical development, or marketing within biopharmaceutical companies, this personalized program is specifically designed to equip you with the essential knowledge and skills needed to excel in these burgeoning fields.

During the program, participants will have exclusive access to seasoned industry professionals who will provide invaluable guidance and mentorship, immersing them in hands-on HEOR and RWD/RWE projects. By the program’s conclusion, you will have gained practical experience and exposure to real-world projects, along with a solid foundation in workplace etiquette, common-sense practices, and effective communication. This comprehensive training experience will empower you to make informed decisions regarding your next career steps and future development plans.

Take the first step toward a rewarding career in RWD/RWE, and HEOR by sending an email directly to info@polygonhealthanalytics.com with the subject line “Launchpad Program”. We pledge to review your resume carefully and get back to you within 2 weeks. 

Background:

  • At Polygon Health Analytics, we draw inspiration from our founder, Dr. Lixia Yao and remain dedicated to cultivating a supportive learning environment that nurtures the growth and development of young talents in the workplace. We firmly believe in the untapped potential within each individual, and our team is here to guide you towards achieving your professional aspirations.
  • While clinical trials play a vital role in the development and evaluation of new pharmaceuticals and vaccines, they often fail to capture the complete range of real-world outcomes and impacts of these interventions. Once a new intervention receives regulatory approval, it is prescribed to a diverse patient population with varying ages, medical histories, and concurrent medications, extending beyond the scope of the clinical trial participants. As a result, the true clinical and cost effectiveness of the intervention in real-world settings requires additional investigation. Additionally, manufacturers are obligated to monitor the post-marketing safety of their products. Real-world data (RWD), real-world evidence (RWE), and health economics and outcomes research (HEOR) play a critical role in the lifecycle of pharmaceuticals and vaccines, by bridging the gap between controlled clinical trials and real-world practice.